Proposal for a noradrenaline hypothesis of schizophrenia

Progress in Neuro-psychopharmacology & Biological Psychiatry
Kenichi Yamamoto, Oleh Hornykiewicz

Abstract

In this article, we have reevaluated the role of noradrenergic dysfunction in the pathogenesis of schizophrenia in the light of today's neuroscience and clinical data. Neurophysiological, psychophysiological, psychopharmacological, and biochemical findings that have accumulated in last decades indicate that certain noradrenergic dysfunctions play important roles in the pathogenesis of the disorder. Moreover, these findings provide us with consistent evidence for the existence of two syndromes generated by either overactivity or underactivity of the central noradrenaline (NA) system. The former appears to correspond to the type I syndrome (positive symptoms) and the latter to the type II syndrome (negative symptoms). We conclude that the involvement of brain NA in cerebral metabolism and blood flow as well as the amine's role in brain development and neuronal differentiation may provide the mechanisms underlying the disease process in schizophrenia. Development of chemical agents acting specifically on the brain noradrenergic mechanisms may be a promising approach to novel treatments of the disorder.

References

Mar 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·T J CrowW S Killpack
Jan 1, 1977·Progress in Neurobiology·D G Amaral, H M Sinnamon
Jan 1, 1978·Acta Psychiatrica Scandinavica. Supplementum·M AsbergG Sedvall
Jul 1, 1979·Acta Psychiatrica Scandinavica·B WinbladB E Roos
Dec 1, 1976·Archives of General Psychiatry·P S HolzmanL R Proctor
Aug 11, 1975·Archives of General Psychiatry·R M PostF K Goodwin
Aug 15, 1991·The New England Journal of Medicine·L J FriedmanM Sved
Nov 1, 1990·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·B SaletuK Steinberger
Sep 1, 1990·The Japanese Journal of Psychiatry and Neurology·G Tomiyama
Oct 1, 1989·Archives of General Psychiatry·M S KramerI Kimes
Jun 1, 1985·The Journal of Nervous and Mental Disease·J G CsernanskyL E Hollister
Jan 1, 1985·International Journal of Psychiatry in Medicine·S R Kay, L A Opler
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Oct 1, 1987·Archives of General Psychiatry·W M GlazerG R Heninger
Mar 1, 1970·The American Journal of Psychiatry·D J KupferF Snyder
Feb 1, 1973·Archives of General Psychiatry·D S JanowskyH J Sekerke
Jul 13, 1973·Science·P S HolzmanD W Hughes
Jan 12, 1980·British Medical Journal·T J Crow
Jul 1, 1983·Archives of General Psychiatry·D E SternbergW E Bunney
May 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·S L FooteF E Bloom
Jan 1, 1981·Psychopharmacology·L M Adams, M A Geyer
Jan 1, 1982·Psychopharmacology·B AngristJ Rotrosen
Mar 1, 1982·The American Journal of Psychiatry·N C AndreasenM R Smith
Aug 1, 1981·The American Journal of Psychiatry·D E SternbergW E Bunney
Jan 18, 1980·Science·C R LakeW E Bunney

❮ Previous
Next ❯

Citations

May 21, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Fuad Lechin, Bertha van der Dijs
Apr 22, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Karen M Alsene, Vaishali P Bakshi
May 17, 2007·Schizophrenia Bulletin·William S Stone, Larry J Seidman
Jan 1, 2009·BMJ Case Reports·Joaquim Alves da SilvaMiguel Xavier
Oct 10, 2013·Schizophrenia Bulletin·Bob Oranje, Birte Y Glenthøj
Mar 24, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Matthew A AlbrechtMathew T Martin-Iverson
Jun 15, 2011·Brain, Behavior, and Immunity·Urs Meyer
Mar 24, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Roland M DardennesFrédéric Rouillon
Jun 24, 2008·Journal of Theoretical Biology·Anca Radulescu
Apr 10, 2014·The European Journal of Neuroscience·Richard J GardnerUllrich Bartsch
Jan 1, 2014·Psychiatry and Clinical Neurosciences·Ken-ichi YamamotoMitsunobu Yoshii
Oct 10, 2006·Brain Research Bulletin·C Winograd-GurvichO B White
Sep 18, 2013·Psychiatry Research·Marija BoškovićTomaž Vovk
Jan 15, 2015·Pharmacology & Therapeutics·William T O'Connor, Sean D O'Shea
Jun 16, 2015·Frontiers in Human Neuroscience·Tamara Anne Russell, Silvia Maria Arcuri
May 11, 2010·Journal of Neuroscience Methods·Mathias Benedek, Christian Kaernbach
May 8, 2008·The International Journal of Neuropsychopharmacology·Aarthi KamathLalit K Srivastava
Jul 28, 2016·Environmental Toxicology and Pharmacology·P RatajczakE Nowakowska
Jul 28, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Marco BortolatoJackob Moskovitz
Mar 31, 2017·International Journal of Molecular Sciences·Matea Nikolac PerkovicNela Pivac
Aug 5, 2017·Drugs·Selene R T VeermanLieuwe de Haan
May 22, 2018·American Journal of Therapeutics·Ahmed NaguyBader Khraibut
Dec 19, 2007·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·A MéaryP M Llorca
Jul 25, 2013·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Renata S CouraSylvie Granon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Brain Research Bulletin
K YamamotoMitsunobu Yoshii
Progress in Neuro-psychopharmacology & Biological Psychiatry
Fuad Lechin, B van der Dijs
Psychiatry and Clinical Neurosciences
K YamamotoMitsunobu Yoshii
© 2021 Meta ULC. All rights reserved